(DOC) Healthpeak Properties - Ratings and Ratios
Medical Office, Senior Housing, Life Science Properties
DOC EPS (Earnings per Share)
DOC Revenue
Description: DOC Healthpeak Properties
Healthpeak Properties, Inc. (NYSE:DOC) is a fully integrated real estate investment trust (REIT) that specializes in owning, operating, and developing high-quality healthcare-focused real estate. As a member of the S&P 500, the company is a significant player in the healthcare REIT sector.
From a financial perspective, Healthpeak Properties has a market capitalization of $12.7 billion, indicating a substantial presence in the market. The companys price-to-earnings (P/E) ratio is 44.68, suggesting that investors are willing to pay a premium for its shares. Additionally, the forward P/E ratio is 76.34, implying expected earnings growth. The return on equity (ROE) is 3.29%, which is relatively low, indicating that the company may not be generating sufficient profits from its shareholders equity.
To further analyze Healthpeak Properties performance, we can examine key performance indicators (KPIs) such as funds from operations (FFO) per share, which is a crucial metric for REITs. A stable or growing FFO per share indicates a companys ability to generate cash from its operations. Another important metric is the debt-to-equity ratio, which can help assess the companys leverage and financial health. A lower debt-to-equity ratio generally indicates a more stable financial position.
Healthpeak Properties focus on healthcare real estate, including properties related to healthcare discovery and delivery, positions the company for potential long-term growth, driven by the increasing demand for healthcare services. The companys development pipeline and existing portfolio are critical factors in its ability to generate future cash flows and drive shareholder value.
DOC Stock Overview
| Market Cap in USD | 12,321m |
| Sub-Industry | Health Care REITs |
| IPO / Inception | 1987-11-05 |
DOC Stock Ratings
| Growth Rating | -48.4% |
| Fundamental | 61.4% |
| Dividend Rating | 38.3% |
| Return 12m vs S&P 500 | -27.4% |
| Analyst Rating | 4.25 of 5 |
DOC Dividends
| Dividend Yield 12m | 6.51% |
| Yield on Cost 5y | 6.31% |
| Annual Growth 5y | -9.84% |
| Payout Consistency | 97.1% |
| Payout Ratio | 1.9% |
DOC Growth Ratios
| Growth Correlation 3m | 14.5% |
| Growth Correlation 12m | -86% |
| Growth Correlation 5y | -60.9% |
| CAGR 5y | -3.02% |
| CAGR/Max DD 3y | -0.07 |
| CAGR/Mean DD 3y | -0.14 |
| Sharpe Ratio 12m | -0.74 |
| Alpha | -32.59 |
| Beta | 0.951 |
| Volatility | 23.77% |
| Current Volume | 4731.5k |
| Average Volume 20d | 5895.1k |
| Stop Loss | 17.7 (-3%) |
| Signal | 0.84 |
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income (164.9m TTM) > 0 and > 6% of Revenue (6% = 167.7m TTM) |
| FCFTA 0.06 (>2.0%) and ΔFCFTA 1.59pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -5.72% (prev 5.30%; Δ -11.02pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.06 (>3.0%) and CFO 1.24b > Net Income 164.9m (YES >=105%, WARN >=100%) |
| Net Debt (9.19b) to EBITDA (1.60b) ratio: 5.76 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.83 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (697.1m) change vs 12m ago -0.87% (target <= -2.0% for YES) |
| Gross Margin 60.42% (prev 59.59%; Δ 0.83pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 13.98% (prev 11.95%; Δ 2.03pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 1.73 (EBITDA TTM 1.60b / Interest Expense TTM 292.4m) >= 6 (WARN >= 3) |
Altman Z'' -1.24
| (A) -0.01 = (Total Current Assets 806.0m - Total Current Liabilities 965.8m) / Total Assets 19.81b |
| (B) -0.28 = Retained Earnings (Balance) -5.53b / Total Assets 19.81b |
| (C) 0.03 = EBIT TTM 506.4m / Avg Total Assets 19.99b |
| (D) -0.43 = Book Value of Equity -4.84b / Total Liabilities 11.22b |
| Total Rating: -1.24 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 61.41
| 1. Piotroski 4.50pt = -0.50 |
| 2. FCF Yield 5.85% = 2.93 |
| 3. FCF Margin 44.52% = 7.50 |
| 4. Debt/Equity 1.14 = 1.88 |
| 5. Debt/Ebitda 5.67 = -2.50 |
| 6. ROIC - WACC -2.92% = -3.65 |
| 7. RoE 1.99% = 0.17 |
| 8. Rev. Trend 93.72% = 7.03 |
| 9. EPS Trend -29.04% = -1.45 |
What is the price of DOC shares?
Over the past week, the price has changed by -0.27%, over one month by +6.06%, over three months by +7.71% and over the past year by -13.72%.
Is Healthpeak Properties a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of DOC is around 17.13 USD . This means that DOC is currently overvalued and has a potential downside of -6.14%.
Is DOC a buy, sell or hold?
- Strong Buy: 10
- Buy: 5
- Hold: 5
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the DOC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 21.5 | 18% |
| Analysts Target Price | 21.5 | 18% |
| ValueRay Target Price | 18.7 | 2.2% |
Last update: 2025-09-05 04:39
DOC Fundamental Data Overview
CCE Cash And Equivalents = 89.4m USD (last quarter)
P/E Trailing = 73.875
P/E Forward = 74.6269
P/S = 4.4072
P/B = 1.5734
P/EG = 4.0809
Beta = 1.019
Revenue TTM = 2.80b USD
EBIT TTM = 506.4m USD
EBITDA TTM = 1.60b USD
Long Term Debt = 9.04b USD (from longTermDebt, last quarter)
Short Term Debt = 1.85m USD (from shortTermDebt, last quarter)
Debt = 9.04b USD (Calculated: Short Term 1.85m + Long Term 9.04b)
Net Debt = 9.19b USD (from netDebt column, last quarter)
Enterprise Value = 21.27b USD (12.32b + Debt 9.04b - CCE 89.4m)
Interest Coverage Ratio = 1.73 (Ebit TTM 506.4m / Interest Expense TTM 292.4m)
FCF Yield = 5.85% (FCF TTM 1.24b / Enterprise Value 21.27b)
FCF Margin = 44.52% (FCF TTM 1.24b / Revenue TTM 2.80b)
Net Margin = 5.90% (Net Income TTM 164.9m / Revenue TTM 2.80b)
Gross Margin = 60.42% ((Revenue TTM 2.80b - Cost of Revenue TTM 1.11b) / Revenue TTM)
Tobins Q-Ratio = -4.40 (set to none) (Enterprise Value 21.27b / Book Value Of Equity -4.84b)
Interest Expense / Debt = 0.83% (Interest Expense 75.1m / Debt 9.04b)
Taxrate = 1.60% (4.35m / 271.7m)
NOPAT = 498.3m (EBIT 506.4m * (1 - 1.60%))
Current Ratio = 0.83 (Total Current Assets 806.0m / Total Current Liabilities 965.8m)
Debt / Equity = 1.14 (Debt 9.04b / last Quarter total Stockholder Equity 7.93b)
Debt / EBITDA = 5.67 (Net Debt 9.19b / EBITDA 1.60b)
Debt / FCF = 7.27 (Debt 9.04b / FCF TTM 1.24b)
Total Stockholder Equity = 8.27b (last 4 quarters mean)
RoA = 0.83% (Net Income 164.9m, Total Assets 19.81b )
RoE = 1.99% (Net Income TTM 164.9m / Total Stockholder Equity 8.27b)
RoCE = 2.93% (Ebit 506.4m / (Equity 8.27b + L.T.Debt 9.04b))
RoIC = 2.92% (NOPAT 498.3m / Invested Capital 17.07b)
WACC = 5.84% (E(12.32b)/V(21.36b) * Re(9.52%)) + (D(9.04b)/V(21.36b) * Rd(0.83%) * (1-Tc(0.02)))
Shares Correlation 3-Years: 66.67 | Cagr: 2.25%
Discount Rate = 9.52% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 76.79% ; FCFE base≈1.13b ; Y1≈1.39b ; Y5≈2.37b
Fair Price DCF = 44.51 (DCF Value 30.93b / Shares Outstanding 694.9m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: -29.04 | EPS CAGR: -42.89% | SUE: 0.0 | # QB: False
Revenue Correlation: 93.72 | Revenue CAGR: 11.06%
Additional Sources for DOC Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle